文献速递妇科

MEK抑制剂曲美替尼联合AKT抑制剂GSK2141795治疗复发性子宫内膜癌的安全性导入研究:NRG肿瘤学/GOG研究

Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.
PubMed 文献 · Gynecol Oncol · 2019-10-15

本研究在复发性子宫内膜癌患者中评估MEK抑制剂曲美替尼联合AKT抑制剂GSK2141795的安全性与疗效。26例入组,DL1(曲美替尼1.5 mg联合GSK2141795 50 mg)出现8例剂量限制性毒性,判定不可耐受;DL-1(GSK2141795减至25 mg)无剂量限制性毒性。DL1无缓解,DL-1有1例缓解;因可耐受剂量下初步疗效不足,II期研究未启动。

要点

  • DL1(曲美替尼1.5 mg联合GSK2141795 50 mg)出现8例剂量限制性毒性,判定不可耐受。
  • DL-1(GSK2141795减至25 mg)无剂量限制性毒性,但仅1例缓解。
  • 因可耐受剂量下初步疗效不足,II期研究未启动。

核心结论

  • 曲美替尼联合GSK2141795在既往推荐的2期剂量下于子宫内膜癌中毒性水平高,但在降低剂量后可耐受。
  • 由于可耐受剂量下初步疗效不足,II期研究未启动。

研究设计与样本

  • 安全导入研究,纳入可测量复发性子宫内膜癌患者,允许1至2种既往细胞毒方案,排除既往使用MEK或PI3K通路抑制剂者。
  • 初始试验设计为KRAS突变分层随机II期研究,包含评估联合方案的安全性导入。
  • 安全导入中,剂量水平1(DL1)采用既往推荐的2期剂量(RP2D):曲美替尼1.5 mg联合GSK2141795 50 mg。
  • 共26例入组,14例在DL1治疗,12例在DL-1治疗(曲美替尼1.5 mg联合GSK2141795 25 mg)。

主要发现

  • 最常见组织学类型为子宫内膜样(58%)和浆液性(27%)。
  • 25例中有4例(16%)为KRAS突变。
  • DL1出现8例剂量限制性毒性:高血压(n=2)、黏膜炎(2)、皮疹(2)、脱水、卒中/急性肾损伤。
  • DL1被判定为不可耐受,遂探索DL-1;DL-1无剂量限制性毒性。
  • 65%的患者发生≥3级毒性。

局限性

  • 由于可耐受剂量下初步疗效不足,II期研究未启动。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We sought to determine safety and efficacy of the AKT inhibitor, GSK2141795, combined with the MEK inhibitor, trametinib, in endometrial cancer. METHODS: Patients with measurable recurrent endometrial cancer were eligible. One to two prior cytotoxic regimens were allowed; prior use of a MEK or PI3K pathway inhibitor was excluded. Initial trial design consisted of a KRAS mutation stratified randomized phase II with a safety lead-in evaluating the combination. For the safety lead in, the previously recommended phase 2 dose (RP2D; trametinib 1.5 mg, GSK2141795 50 mg) was chosen for Dose Level 1 (DL1). RESULTS: Of 26 enrolled patients, 14 were treated on DL1 and 12 were treated on DL-1 (trametinib 1.5 mg, GSK2141795 25 mg). Most common histologies were endometrioid (58%) and serous (27%). Four of 25 (16%) patients were KRAS mutant. Dose limiting toxicities (DLTs) were assessed during cycle 1. DL1 had 8 DLTs (hypertension (n = 2), mucositis (2), rash (2), dehydration, stroke/acute kidney injury). DL1 was deemed non-tolerable so DL-1 was explored. DL-1 had no DLTs. Sixty-five percent of patients had ≥ grade 3 toxicity. There were no responses in DL1 (0%, 90%CI 0-15%) and 1 response in DL-1 (8.3%, 90%CI 0.4-33.9%). Proportion PFS at 6 months for DL1 is 14%, and 25% for DL-1. CONCLUSION: The combination of trametinib and GSK2141795 had high levels of toxicity in endometrial cancer at the previously RP2D but was tolerable at a reduced dose. Due to insufficient preliminary efficacy at a tolerable dose, the Phase II study was not initiated.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Westin SN, Sill MW, Coleman RL, et al. Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. Gynecol Oncol. 2019. PMID: 31623857. doi:10.1016/j.ygyno.2019.09.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。